TY - JOUR
T1 - Matrix-comparative genomic hybridization from multicenter formalin-fixed paraffin-embedded colorectal cancer tissue blocks
AU - Fensterer, Heiko
AU - Radlwimmer, Bernhard
AU - Sträter, Jörn
AU - Buchholz, Malte
AU - Aust, Daniela E.
AU - Julié, Catherine
AU - Radvanyi, François
AU - Nordlinger, Bernard
AU - Belluco, Claudio
AU - Van Cutsem, Eric
AU - Köhne, Claus Henning
AU - Kestler, Hans A.
AU - Schwaenen, Carsten
AU - Nessling, Michelle
AU - Lutz, Manfred P.
AU - Lichter, Peter
AU - Gress, Thomas M.
PY - 2007/4/2
Y1 - 2007/4/2
N2 - Background: The identification of genomic signatures of colorectal cancer for risk stratification requires the study of large series of cancer patients with an extensive clinical follow-up. Multicentric clinical studies represent an ideal source of well documented archived material for this type of analyses. Methods: To verify if this materialis technically suitable to perform matrix-CGH, we performed a pilot study using macrodissected 29 formalin-fixed, paraffin-embedded tissue samples collected within the framework of the EORTC-GI/PETACC-2 trial for colorectal cancer. The scientific aim was to identify prognostic genomic signatures differentiating locally restricted (UICC stages II-III) from systemically advanced (UICC stage IV) colorectal tumours. Results: The majority of archived tissue samples collected in the different centers was suitable to perform matrix-CGH. 5/7 advanced tumours displayed 13q-gain and 18q-loss. In locally restricted tumours, only 6/12 tumours showed a gain on 13q and 7/12 tumours showed a loss on 18q. Interphase-FISH and high-resolution array-mapping of the gain on 13q confirmed the validity of the array-data and narrowed the chromosomal interval containing potential oncogenes. Conclusion: Archival, paraffin-embedded tissue samples collected in multicentric clinical trials are suitable for matrix-CGH analyses and allow the identification of prognostic signatures and aberrations harbouring potential new oncogenes.
AB - Background: The identification of genomic signatures of colorectal cancer for risk stratification requires the study of large series of cancer patients with an extensive clinical follow-up. Multicentric clinical studies represent an ideal source of well documented archived material for this type of analyses. Methods: To verify if this materialis technically suitable to perform matrix-CGH, we performed a pilot study using macrodissected 29 formalin-fixed, paraffin-embedded tissue samples collected within the framework of the EORTC-GI/PETACC-2 trial for colorectal cancer. The scientific aim was to identify prognostic genomic signatures differentiating locally restricted (UICC stages II-III) from systemically advanced (UICC stage IV) colorectal tumours. Results: The majority of archived tissue samples collected in the different centers was suitable to perform matrix-CGH. 5/7 advanced tumours displayed 13q-gain and 18q-loss. In locally restricted tumours, only 6/12 tumours showed a gain on 13q and 7/12 tumours showed a loss on 18q. Interphase-FISH and high-resolution array-mapping of the gain on 13q confirmed the validity of the array-data and narrowed the chromosomal interval containing potential oncogenes. Conclusion: Archival, paraffin-embedded tissue samples collected in multicentric clinical trials are suitable for matrix-CGH analyses and allow the identification of prognostic signatures and aberrations harbouring potential new oncogenes.
UR - http://www.scopus.com/inward/record.url?scp=34247400139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247400139&partnerID=8YFLogxK
U2 - 10.1186/1471-2407-7-58
DO - 10.1186/1471-2407-7-58
M3 - Article
C2 - 17407575
AN - SCOPUS:34247400139
SN - 1471-2407
VL - 7
JO - BMC Cancer
JF - BMC Cancer
M1 - 58
ER -